UBS Reiterates Buy on Pfizer (PFE) Following a Meeting with Management
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq set to fall at open as DeepSeek's AI chip push rattles markets
- Oil gains after vessels attacked near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Pfizer Completes Acquisition of Medivation
September 28, 2016 8:50 AM EDTTender offer for all of the outstanding shares of Medivation common stock expired as scheduled one minute after 11:59 p.m., Eastern time, on September 27, 2016 Pfizer and Medivation begin joint operations on September 28, 2016 Combined expertise accelerates Pfizers leadership in Oncology, bringing much-needed new cancer treatments to patients Expected to be immediately accretive to Pfizers Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth anticipated thereafter... More
Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress
September 28, 2016 6:00 AM EDT20 abstracts across multiple tumor types; unique mechanisms of action address the diverse needs of people living with cancer
New combination study data in renal cell carcinoma and first-in-human results for OX40 agonist provide new insights in immuno-oncology
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11, 2016. The presentations demonstrate progress addressing cancers complex challenges through our work across 11 tumor types and... More
